Published 2021
| Version v1
Publication
Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial
- Creators
- Uccelli, Antonio
- Laroni, Alice
- Ali, Rehiana
- Battaglia, Mario Alberto
- Blinkenberg, Morten
- Brundin, Lou
- Clanet, Michel
- Fernandez, Oscar
- Marriot, James
- Muraro, Paolo
- Nabavi, Seyed Massood
- Oliveri, Roberto S
- Radue, Ernst
- Ramo Tello, Cristina
- Schiavetti, Irene
- Sellner, Johann
- Sorensen, Per Soelberg
- Sormani, Maria Pia
- Wuerfel, Jens Thomas
- Freedman, Mark S
- Others:
- Uccelli, Antonio
- Laroni, Alice
- Ali, Rehiana
- Battaglia, Mario Alberto
- Blinkenberg, Morten
- Brundin, Lou
- Clanet, Michel
- Fernandez, Oscar
- Marriot, Jame
- Muraro, Paolo
- Nabavi, Seyed Massood
- Oliveri, Roberto S
- Radue, Ernst
- Ramo Tello, Cristina
- Schiavetti, Irene
- Sellner, Johann
- Sorensen, Per Soelberg
- Sormani, Maria Pia
- Wuerfel, Jens Thoma
- Freedman, Mark S
Description
Mesenchymal stem cells (MSCs), also known as mesenchymal stromal cells, have been proposed as a promising therapeutic option for people with multiple sclerosis on the basis of their immunomodulatory and neuroprotective properties. The MEsenchymal StEm cells for Multiple Sclerosis (MESEMS) study was devised to evaluate the safety, tolerability, and activity of autologous MSCs derived from bone marrow and infused intravenously in patients with active multiple sclerosis.
Additional details
- URL
- http://hdl.handle.net/11567/1060382
- URN
- urn:oai:iris.unige.it:11567/1060382
- Origin repository
- UNIGE